跳至主要内容
临床试验/NCT03823274
NCT03823274已完成不适用

Multi-center, Prospective, Cohort Study to Evaluate the Relationship of Stroke Recurrence and Anti-platelet Resistance in Ischemic Stroke Patients

Yuhan Corporation1 个研究点 分布在 1 个国家目标入组 1,011 人开始时间: 2019年4月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,011
试验地点
1
主要终点
evaluate the relationship of stroke recurrence and anti-platelet resitance

研究概览

简要总结

This cohort study will evaluate the relatiobship of stroke recurrence and anti-platelet resistance in ischemic stroke patients

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
60 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women over 60 years old at the time of written consent
  • Those admitted to the hospital within 72 hours after acute cerebral infarction and treated with Aspirin 100 mg and Clopidogrel 75 mg
  • Written informed consent voluntarily signed

排除标准

  • Those with evidence other brain lesions such as brain tumors
  • Those who need oral anticoagulants other than vitamin K antagonists or anticoagulant therapy of warfarin
  • Contraindicate to Aspirin or Clopidogrel or allergic to the drug
  • Subjects who are at risk of active pathological bleeding such as digestive ulcer and intracranial hemorrhage
  • Cancer disease that can shorten life expectancy
  • Patient's condition that may interfere with participation in study such as mental illness, mental retardation, dementia, drug abuse, and alcoholism
  • Subjects other than the above unsuitable for this clinical study identified by Investigator

结局指标

主要结局

evaluate the relationship of stroke recurrence and anti-platelet resitance

时间窗: 12weeks

To evaluate the relationship of stroke recurrence and anti-platelet resitance in ischemic stroke patients receiving aspirin 10mmg and clopidogrel 75mg for 12weeks

次要结局

未报告次要终点

研究者

发起方
Yuhan Corporation
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验